Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, COVID-19 virus infection, Date of authorisation: 25/03/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, COVID-19 virus infection, Date of authorisation: 25/03/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging;Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging;Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Prostatic Neoplasms, Date of authorisation: 24/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Prostatic Neoplasms, Date of authorisation: 24/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma;Urticaria, Date of authorisation: 25/10/2005, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma;Urticaria, Date of authorisation: 25/10/2005, Revision: 48, Status: Authorised

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010649/202302

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010649/202302

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202302

ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus), ibuprofen / caffeine : List of nationally authorised medicinal products - PSUSA/00010649/202302

Human medicines European public assessment report (EPAR): Omidria, phenylephrine,ketorolac, Lens Implantation, Intraocular;Pain, Postoperative, Date of authorisation: 28/07/2015, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Omidria, phenylephrine,ketorolac, Lens Implantation, Intraocular;Pain, Postoperative, Date of authorisation: 28/07/2015, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Revision: 13, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness